AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 14647985
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of ROLL procedure with direct injection of MAA into the lesion and lymphoscintigraphy with subdermal injection of radiocolloids
Trial: 11707007
Drug: Etidronate (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etidronate (400 mg/d cyclically for 14 days with 76-day intervals, plus calcium and vitamin D)
Trial: 11707007
Drug: Alendronate (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alendronate (10 mg/d daily)
Trial: 1096666
Drug: Intravenous hyoscine
RxNorm normalized name: HYOSCINE HYDROBROMIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hyoscine butylbromide (Buscopan)
Trial: 18373526
Drug: Vardenafil 10
RxNorm normalized name: vardenafil 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vardenafil 10 mg (titrated to 5 mg or 20 mg based on efficacy and safety)
Trial: 16434427
Drug: Selective ET‐A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective ET‐A antagonist, BQ‐123 (n = 8) at 1000 and 3000 nmol/min
Trial: 16434427
Drug: Selective ET‐B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Selective ET‐B antagonist, BQ‐788 (n = 8) at 100 and 300 nmol/min
Trial: 12432293
Drug: Topical 0.3%
RxNorm normalized name: triclosan topical 0.3% topical bar
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 0.3% nifedipine and 1.5% lidocaine ointment every 12 hours for 6 weeks
Trial: 12432293
Drug: Topical 1.5%
RxNorm normalized name: phenol topical 1.5% topical liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical 1.5% lidocaine and 1% hydrocortisone acetate ointment
Trial: 7726809
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for social phobia (used for both refusers and excluded subjects)
Trial: 7726809
Drug: Cognitive-behavioral treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-behavioral treatment for social phobia (for acceptors)
Trial: 2193461
Drug: Flutamide plus
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide plus leuprolide (LHRH-agonist)
Trial: 2193461
Drug: Flutamide monotherapy
RxNorm normalized name: Flutamide
DrugBank: Flutamide (DB00499)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Flutamide monotherapy
Trial: 2193461
Drug: Flutamide in
RxNorm normalized name: Product containing flutamide in oral dose form (medicinal product form)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Flutamide in combination with LHRH-agonist
Trial: 6432398
Drug: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 600 mg
Trial: 6432398
Drug: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DL-Threo-3,4-dihydroxyphenylserine (DL-DOPS) 800 mg
Trial: 24675683
Drug: Dieting implementation
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dieting implementation intentions (e.g., If I open the fridge I will think of dieting!)
Trial: 22269428
Drug: Enzastaurin plus
RxNorm normalized name: Enzastaurin
DrugBank: Enzastaurin (DB06486)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin plus cisplatin-pemetrexed (125 or 250 mg twice daily)
Trial: 17623381
Drug: Traditional ward
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Traditional ward occupational therapy (WOT) programme (n = 37)
Trial: 16041193
Drug: Colesevelam HCl
RxNorm normalized name: colesevelam HCl
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam HCl and ezetimibe combination therapy
Trial: 11993618
Drug: Glycerol loading
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glycerol loading (1.2 g of glycerol per kg of body mass and 25 ml of a 0.75 g x kg(‐1) BM carbohydrate solution consumed over 60 minutes, 2 hours prior to ODT)
Trial: 10568224
Drug: Alendronate plus
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate plus calcium (10 mg alendronate + 500 mg calcium/day)
Trial: 10568224
Drug: Alendronate plus
RxNorm normalized name: alendronate
DrugBank: Alendronic acid (DB00630)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Alendronate plus calcitriol (0.25 microgram synthetic 1,25‐dihydroxyvitamin D3 + 10 mg alendronate)
Trial: 7725591
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of SN + PR
Trial: 2183488
Drug: Diclofenac sodium
RxNorm normalized name: Diclofenac Sodium
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac sodium 75 mg intramuscular (im)
Trial: 2183488
Drug: Baralgin 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Baralgin 5 mL intravenous (iv)
Trial: 23704830
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (routine western medicine)
Trial: 26671216
Drug: Robot only
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Robot only (60 minutes of robotic therapy)
Trial: 22898992
Drug: Sildenafil (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sildenafil (100 mg, single dose)
Trial: 22898992
Drug: Sodium Nitroprusside
RxNorm normalized name: Sodium Nitroprusside
DrugBank: Nitroprusside (DB00325)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sodium Nitroprusside (1 ‐ 2 µg/kg/min)
Trial: 15611850
Drug: Hypnotherapeutic treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hypnotherapeutic treatment program (n=10)
Trial: 12218617
Drug: Prostaglandin E1
RxNorm normalized name: Prostaglandin E1
DrugBank: Alprostadil (DB00770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Prostaglandin E1 (PGE1) with 60 microg and 100 mg hydrocortisone for 7 days
Trial: 12218617
Drug: Placebo with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo with 100 mg hydrocortisone
Trial: 10624762
Drug: Methacholine challenge
RxNorm normalized name: Methacholine Challenge Kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methacholine challenge (concentration up to 128 mg x mL(‐1))
Trial: 7496872
Drug: Erythromycin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Erythromycin (150 mg/h)
Trial: 2044501
Drug: Felbamate (FBM)
RxNorm normalized name: Felbamate
DrugBank: Felbamate (DB00949)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Felbamate (FBM) 50 mg/kg per day (maximum 3,000 mg)
Trial: 7019201
Drug: Single daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single daily doses of amoxapine
Trial: 7019201
Drug: Divided daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Divided daily doses of amoxapine
Trial: 16464721
Drug: Therapy (specifics
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapy (specifics not provided)
Trial: 21137794
Drug: LF-SQ cream
RxNorm normalized name: HYDROXYPROPYL CELLULOSE LF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF-SQ cream applied twice daily on one half of the face
Trial: 21137794
Drug: LF-SQ cream
RxNorm normalized name: HYDROXYPROPYL CELLULOSE LF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LF-SQ cream
Trial: 21137794
Drug: Placebo (squalane
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (squalane blended cream without fullerene-C60)
Trial: 18201449
Drug: Rabeprazole, 20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rabeprazole, 20 mg, orally twice daily for 90 days
Trial: 15797496
Drug: Low dose
RxNorm normalized name: Low Dose ASA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low dose pulsed shortwave (10 W)
Trial: 15797496
Drug: High dose
RxNorm normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High dose pulsed shortwave (20 W)
Trial: 12372721
Drug: Systemic adjuvant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Systemic adjuvant chemotherapy
Trial: 12372721
Drug: Hepatic-artery-based chemotherapy
RxNorm normalized name: Sus scrofa artery preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hepatic-artery-based chemotherapy or embolisation
Trial: 12372721
Drug: Other therapeutic
RxNorm normalized name: Other therapeutic products
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other therapeutic modalities (immunological, radiation, differentiation agents)
Trial: 2686455
Drug: Triphasic oral
RxNorm normalized name: CeeNU, triphasic oral capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triphasic oral contraceptives (1) ethinyl estradiol 30, 40, 30 micrograms/day and levonorgestrel 50, 75, 125 micrograms/day; (2) ethinyl estradiol 35 micrograms/day and phased norethindrone 500, 750, 1000 micrograms/day; (3) ethinyl estradiol 35 micrograms/day and norethindrone 500, 1000, 500 micrograms/day
Trial: 31734734
Drug: Probiotic product
RxNorm normalized name: Rezyst Probiotic Oral Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic product (Lactobacillus plantarum HEAL9 and Lactobacillus paracasei 8700:2) 109 CFU once daily for 3 months
Trial: 22319592
Drug: Doxazosin (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Doxazosin (1 mg PO/day, increased every three days by 1 mg up to 4 mg)
Trial: 18394742
Drug: Functional retraining
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional retraining programme with daily isokinetic reinforcement of the trunk muscles
Trial: 18394742
Drug: Functional retraining
RxNorm normalized name: plasma protein fraction Injection [Plasmanate]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Functional retraining programme without daily isokinetic reinforcement of the trunk muscles (Control Group)
Trial: 11693896
Drug: Zoledronic acid
RxNorm normalized name: Zoledronic Acid
DrugBank: Zoledronic acid (DB00399)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Zoledronic acid (4 mg)
Trial: 15607868
Drug: Pamidronate (90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pamidronate (90 mg)
Trial: 11012611
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of pulmonary TB for 6 months
Trial: 11012611
Drug: Asthma patients
RxNorm normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Asthma patients (no treatment)
Trial: 7678931
Drug: finasteride 1
RxNorm normalized name: finasteride 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: finasteride 1 mg/day and finasteride 5 mg/day (combined results)
Trial: 21467697
Drug: N-acetylcysteine (NAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC, 705 mg orally before and 12, 24, 36 hours after primary angioplasty)
Trial: 21222064
Drug: Pitavastatin (2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pitavastatin (2 mg daily)
Trial: 15505610
Drug: High-dose cyclophosphamide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose cyclophosphamide, carmustine, and thiotepa (CBT) followed by autologous hematopoietic stem cell transplantation (AHST)
Trial: 15505610
Drug: High-dose CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose CBT followed by AHST
Trial: 1888641
Drug: Cromakalim 2.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim 2.0 mg
Trial: 1888641
Drug: Cromakalim 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cromakalim 1.0 mg and 2.0 mg
Trial: 6669636
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg zopiclone
Trial: 23726161
Drug: Inactivated alum-adjuvant
RxNorm normalized name: alum
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactivated alum-adjuvant EV71 vaccine
Trial: 21897013
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation 1 mg/d for 4 or 12 weeks
Trial: 21897013
Drug: Astaxanthin supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astaxanthin supplementation 3 mg/d for 4 or 12 weeks
Trial: 15507582
Drug: Combined CBT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined CBT and sertraline
Trial: 12102584
Drug: Habit reversal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Habit reversal treatment in a minimal therapist contact (MTC) format
Trial: 23629822
Drug: HMG-CoA reductase
RxNorm normalized name: HMG-CoA reductase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HMG-CoA reductase inhibitors (statins)
Trial: 8129214
Drug: Theo-24 (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-24 (800 mg daily)
Trial: 8129214
Drug: Theo-Dur (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Theo-Dur (800 mg daily)
Trial: 1093461
Drug: mini-dose heparin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mini-dose heparin
Trial: 31327131
Drug: Resveratrol 800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Resveratrol 800 mg/day for 40 days
Trial: 28724799
Drug: Galantamine 8
RxNorm normalized name: galantamine 8 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Galantamine 8 mg daily for 4 weeks, followed by 16 mg daily for 8 weeks
Trial: 25239489
Drug: Continued cognitive-behavior
RxNorm normalized name: Ivy Dry Super Continuous Spray
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Continued cognitive-behavior therapy (CBT) for 16 weeks
Trial: 25239489
Drug: Sertraline (SRT)
DrugBank: Sertraline (DB01104)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sertraline (SRT) for 16 weeks
Trial: 9411502
Drug: Non-steroid treated
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Non-steroid treated patients
Trial: 9338926
Drug: Steroid treated
RxNorm normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Steroid treated patients
Trial: 8450996
Drug: Prednisone (0.75
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prednisone (0.75 mg/kg/d)
Trial: 8450996
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (Prednisone 0.3 mg/kg/d and Azathioprine 2.5 mg/kg/d)
Trial: 8450996
Drug: Azathioprine (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Azathioprine (2.5 mg/kg/d)
Trial: 27184636
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E 400 mg twice a day (Group A)
Trial: 27184636
Drug: UDCA 300
RxNorm normalized name: UDCA
DrugBank: Ursodeoxycholic acid (DB01586)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UDCA 300 mg twice a day (Group B)
Trial: 12013198
Drug: 20% glycerin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20% glycerin cream
Trial: 12013198
Drug: 4% urea
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% urea and 4% sodium chloride cream
Trial: 12013198
Drug: cream base
RxNorm normalized name: Cream Base
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cream base without glycerin (placebo)
Trial: 7752049
Drug: Low-dose dobutamine
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose dobutamine stress echocardiography
Trial: 475432
Drug: Rectal paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rectal paracetamol (15-20 mg/kg)
Trial: 475432
Drug: Oral paracetamol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral paracetamol (15-20 mg/kg)
Trial: 28654682
Drug: Waiting list
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Waiting list for therapist-led CBT (treatment as usual)
Trial: 25782585
Drug: Upper cervical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Upper cervical manipulative therapy in addition to a multimodal program
Trial: 23886091
Drug: Radiation therapy
RxNorm normalized name: Sensitizers used in photodynamic/radiation therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Radiation therapy (R group)
Trial: 17519263
Drug: Morphine PCIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine PCIA (bolus doses for < or =72 h)
Trial: 9068509
Drug: Felodipine (10
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Felodipine (10 mg/day)
Trial: 11292962
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of alpha tocopherol, rutin, melilotus officinalis, and centella asiatica (oral administration)
Trial: 9733230
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g fish oil concentrate (6.4 g eicosapentaenoic acid and 3.9 g docosahexaenoic acid)
Trial: 9733230
Drug: 18 g
RxNorm normalized name: flotufolastat F 18 gallium
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 18 g placebo
Trial: 25012174
Drug: Indomethacin 75
RxNorm normalized name: indomethacin 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indomethacin 75 mg once daily for 6 weeks
Trial: 25012174
Drug: Eplerenone 150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eplerenone 150 mg once daily for 6 weeks
Trial: 25012174
Drug: Amiloride 20
RxNorm normalized name: amiloride 20 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amiloride 20 mg once daily for 6 weeks
Trial: 12771261
Drug: Intranasal drug
RxNorm normalized name: NALOXONE RESCUE KIT INTRANASAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal drug administration
Trial: 12771261
Drug: Intravenous drug
RxNorm normalized name: Drug Implant
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drug administration
Trial: 10551650
Drug: Neoral 5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neoral 5 mg/kg BDS
Trial: 10551650
Drug: Tacrolimus 0.05
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tacrolimus 0.05 mg/kg BDS
Trial: 1948126
Drug: rIFN alpha
RxNorm normalized name: rIFN-alpha-2a
DrugBank: Interferon alfa-2a (DB00034)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rIFN alpha 2b combined with VBMCP chemotherapy
Trial: 6832208
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg dose of caffeine as an aqueous oral solution
Trial: 6832208
Drug: 5 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/kg dose of caffeine as an intravenous infusion
Trial: 26302817
Drug: 80 mL
RxNorm normalized name: urinary bag 480 mL MISCELL EACH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 80 mL double-balloon catheter
Trial: 26302817
Drug: 30 mL
RxNorm normalized name: Vial M/T 30 mL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mL single-balloon catheter
Trial: 25015214
Drug: All treatments
RxNorm normalized name: All Clear
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: All treatments (PK, DLEK, DSEK)
Trial: 20600555
Drug: 0.01 mol/L
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.01 mol/L lactic acid immersion for 1 week, 1 month, or 3 months at 37 degrees C or 60 degrees C
Trial: 17469693
Drug: Cholinesterase inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cholinesterase inhibitors (e.g., rivastigmine, donepezil)
Trial: 17310311
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPAP and 100 mg sildenafil on demand for intercourse
Trial: 17310311
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of CPAP and sildenafil
Trial: 9112881
Drug: CO2-enriched water
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-enriched water (1200 mg CO2 per kg water; immersion time, twenty minutes)
Trial: 1589232
Drug: Naloxone (up
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Naloxone (up to 8 mg in 20 ml vehicle)
Trial: 25593907
Drug: Extracorporeal photopheresis
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Extracorporeal photopheresis (ECP) administered two consecutive days twice a month
Trial: 25593907
Drug: Cyclosporine A
RxNorm normalized name: CycloSPORINE A
DrugBank: Cyclosporine (DB00091)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cyclosporine A (CsA) at a dosage of 3 mg/kg/day
Trial: 20562693
Drug: Plasma B-type
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Trial: 20562693
Drug: Higher plasma
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher plasma B-type natriuretic peptide and N-terminal fragment of its pro-hormone concentrations
Trial: 18557810
Drug: Upper limb
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Upper limb botulinum toxin-A therapy (UL BTX-A)
Trial: 12066724
Drug: Dexamethasone 100
RxNorm normalized name: Dexamethasone 100 microgram/mL oral solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexamethasone 100 mg before induction of anaesthesia (group 1)
Trial: 8952856
Drug: urokinase therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: urokinase therapy
Trial: 1860787
Drug: Magnesium (Mg)
RxNorm normalized name: Magnesium
DrugBank: Magnesium (DB14513)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium (Mg) pyrrolidone carboxylic acid 360 mg/day
Trial: 3533271
Drug: L-5-hydroxytryptophan
RxNorm normalized name: L-5-hydroxytryptophan
DrugBank: Oxitriptan (DB02959)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-5-hydroxytryptophan